Department of Neurology, Erasmus Medical Center, Rotterdam, the Netherlands.
Department of Clinical Chemistry, VU University Medical Center, Amsterdam, the Netherlands.
PLoS One. 2018 Jun 28;13(6):e0199737. doi: 10.1371/journal.pone.0199737. eCollection 2018.
The gene encoding isocitrate dehydrogenase 1 (IDH1) is frequently mutated in several tumor types including gliomas. The most prevalent mutation in gliomas is a missense mutation leading to a substitution of arginine with histidine at the residue 132 (R132H). Wild type IDH1 catalyzes oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG) whereas mutant IDH1 converts α-KG into D2-hydroxyglutarate (D2HG). Unfortunately, there are few in vivo model systems for IDH-mutated tumors to study the effects of IDH1 mutations in tumor development. We have therefore created transgenic zebrafish lines that express various IDH1 mutants.
IDH1 mutations (IDH1R132H, IDH1R132C and loss-of-function mutation IDH1G70D), IDH1wildtype or eGFP were cloned into constructs with several brain-specific promoters (Nestin, Gfap or Gata2). These constructs were injected into fertilized zebrafish eggs at the one-cell stage.
In total more than ten transgenic zebrafish lines expressing various brain-specific IDH1 mutations were created. A significant increase in the level of D2HG was observed in all transgenic lines expressing IDH1R132C or IDH1R132H, but not in any of the lines expressing IDH1wildtype, IDH1G70D or eGFP. No differences in 5-hydroxymethyl cytosine and mature collagen IV levels were observed between wildtype and mutant IDH1 transgenic fish. To our surprise, we failed to identify any strong phenotype, despite increased levels of the oncometabolite D2HG. No tumors were observed, even when backcrossing with tp53-mutant fish which suggests that additional transforming events are required for tumor formation. Elevated D2HG levels could be lowered by treatment of the transgenic zebrafish with an inhibitor of mutant IDH1 activity.
We have generated a transgenic zebrafish model system for mutations in IDH1 that can be used for functional analysis and drug screening. Our model systems help understand the biology of IDH1 mutations and its role in tumor formation.
编码异柠檬酸脱氢酶 1(IDH1)的基因在包括神经胶质瘤在内的几种肿瘤类型中经常发生突变。神经胶质瘤中最常见的突变是错义突变,导致精氨酸被组氨酸取代残基 132(R132H)。野生型 IDH1 催化异柠檬酸的氧化脱羧生成α-酮戊二酸(α-KG),而突变型 IDH1 将α-KG 转化为 D2-羟戊二酸(D2HG)。不幸的是,目前用于 IDH 突变肿瘤的体内模型系统很少,无法研究 IDH1 突变在肿瘤发生中的作用。因此,我们创建了表达各种 IDH1 突变体的转基因斑马鱼系。
将 IDH1 突变(IDH1R132H、IDH1R132C 和功能丧失突变 IDH1G70D)、IDH1 野生型或 eGFP 克隆到具有几种脑特异性启动子(Nestin、Gfap 或 Gata2)的构建体中。这些构建体在受精卵的单细胞阶段被注射到斑马鱼卵中。
总共创建了十多个表达各种脑特异性 IDH1 突变的转基因斑马鱼系。在表达 IDH1R132C 或 IDH1R132H 的所有转基因系中均观察到 D2HG 水平显著升高,但在表达 IDH1 野生型、IDH1G70D 或 eGFP 的任何系中均未观察到。在野生型和突变型 IDH1 转基因鱼之间,5-羟甲基胞嘧啶和成熟胶原蛋白 IV 水平没有差异。令我们惊讶的是,尽管 D2HG 的水平升高,但我们没有发现任何明显的表型。即使与 tp53 突变鱼回交也没有观察到肿瘤,这表明肿瘤形成还需要其他转化事件。用突变型 IDH1 活性抑制剂处理转基因斑马鱼可降低 D2HG 水平。
我们已经生成了用于 IDH1 突变的转基因斑马鱼模型系统,可用于功能分析和药物筛选。我们的模型系统有助于理解 IDH1 突变的生物学及其在肿瘤形成中的作用。